Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGW1ID)

Drug Name

Sirolimus Drug Info

Synonyms

53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Approved	[1]
Brainstem neoplasm		Approved	[1]
Graft-versus-host disease	4B24	Approved	[1]
Intracranial meningioma		Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Lung lymphangioleiomyomatosis		Approved	[1]
Lymphangioleiomyomatosis	CB07	Approved	[2]
Mucosal melanoma		Approved	[1]
Multiple myeloma	2A83	Approved	[3]
Multiple sclerosis	8A40	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[1]
Organ transplant rejection	NE84	Approved	[4]
Plasma cell myeloma	2A83.1	Approved	[1]
Prostate cancer	2C82.0	Approved	[1]
Salivary gland squamous cell carcinoma		Approved	[1]
Uveitis	9A96.Z	Phase 3	[5]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[6]
Dutch elm disease	8D64	Phase 1/2	[4]
Castration-resistant prostate carcinoma		Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]
Pancreatic acinar cell carcinoma		Investigative	[1]
Polycystic kidney disease	GB8Y	Investigative	[1]
Rheumatoid arthritis	FA20	Investigative	[1]

Therapeutic Class

Immunosuppressive Agents

Cross-matching ID

PubChem CID: 5284616
ChEBI ID: CHEBI:9168
CAS Number: CAS 53123-88-9
TTD Drug ID: DMGW1ID
VARIDT Drug ID: DR00262
INTEDE Drug ID: DR1489
ACDINA Drug ID: D00627

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

DME

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serine/threonine-protein kinase mTOR (mTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Temsirolimus	DMS104F	Renal cell carcinoma	2C90	Approved	[15]
PF-04449913	DMSB068	Chronic myelomonocytic leukaemia	2A40	Approved	[16]
Everolimus	DM8X2EH	Advanced cancer	2A00-2F9Z	Approved	[17]
Novolimus	DM6ZPLQ	Artery stenosis	BD52	Approved	[18]
Zotarolimus	DMRMCXW	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Ridaforolimus	DMLHEU7	Sarcoma	2A60-2C35	Phase 3	[20]
AZD2014	DMOEARH	Solid tumour/cancer	2A00-2F9Z	Phase 2	[21]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[22]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[18]
Salirasib	DMRSU4X	Lung cancer	2C25.0	Phase 2	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting PI3K/AKT/mTOR pathway (PAm pathway)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glypromate	DM0OX31	Neurological disorder	6B60	Phase 4	[23]
ON-01210.Na	DMWYEDX	Acute radiation syndrome	NF00	Phase 1	[24]
------------------------------------------------------------------------------------

Drug(s) Targeting HUMAN mammalian target of rapamycin (mTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Everolimus	DM8X2EH	Advanced cancer	2A00-2F9Z	Approved	[25]
Rapamycin	DM8GRJK	Lymphangioleiomyomatosis	CB07	Investigative	[25]
Sapanisertib	DMYZFNH	Breast cancer	2C60-2C65	Investigative	[26]
------------------------------------------------------------------------------------

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[29]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[30]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[31]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[33]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[34]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[35]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[36]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[37]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[36]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[38]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[39]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[40]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[41]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[43]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[44]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[45]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[46]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[47]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[48]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[49]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[43]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[50]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[51]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[52]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[53]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[13]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[54]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[55]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[56]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[57]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[58]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[59]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[13]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[13]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[12]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[60]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[13]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[13]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[13]
Metronidazole	DMTIVEN	Abscess		Approved	[61]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[62]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[63]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[64]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[65]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[68]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[70]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[71]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Calcineurin subunit B type 1 (PPP3R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[72]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[73]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[74]
Bortezomib	DMNO38U	Leukemia		Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[76]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[77]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[14]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[14]
Tacrolimus	DMZ7XNQ	Graft-versus-host disease	4B24	Approved	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Nuclear receptor ROR-gamma (RORC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[79]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[80]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[81]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[82]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[72]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[83]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[84]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[85]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[86]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[82]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3K/AKT/mTOR pathway (PAm pathway)	TTGQUFK	NOUNIPROTAC	Inhibitor	[7]
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[8]
HUMAN mammalian target of rapamycin (mTOR)	TT7HQAF	MTOR_HUMAN	Inhibitor	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[10]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[13]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Calcineurin subunit B type 1 (PPP3R1)	OTGQNFJQ	CANB1_HUMAN	Drug Response	[14]
Interleukin-2 (IL2)	OTGI4NSA	IL2_HUMAN	Drug Response	[14]
Nuclear receptor ROR-gamma (RORC)	OTUBFRPC	RORG_HUMAN	Drug Response	[14]

------------------------------------------------------------------------------------

References

1	Sirolimus FDA Label
2	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201578.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6031).
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	ClinicalTrials.gov (NCT04341675) Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
7	The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71.
8	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
9	Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14.
10	Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
11	Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. Transplant Proc. 2007 Sep;39(7):2142-4.
12	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13	Drug Interactions Flockhart Table
14	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
15	Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
16	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17	Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
18	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
19	Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
20	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
21	Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
22	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
23	Dendritic spine dysgenesis in Rett syndrome. Front Neuroanat. 2014; 8: 97.
24	ON01210.Na (Ex-RAD ) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355.
25	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
26	Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020
27	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
28	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
29	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
30	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
31	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
32	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
33	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
34	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
35	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
36	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
37	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
38	The effect of SLCO1B115 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B115. Pharmacogenet Genomics. 2008 May;18(5):424-33.
39	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
40	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
41	FDA Drug Development and Drug Interactions
42	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
43	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
44	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
45	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
46	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
47	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
48	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
49	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
50	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
51	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
52	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
53	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
54	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
55	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
56	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
57	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
58	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
59	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
60	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
61	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
62	Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
63	Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999 Mar;30(3):376-82. doi: 10.1016/s0168-8278(99)80093-2.
64	Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am J Gastroenterol. 1992 Apr;87(4):465-70.
65	Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol. 2005 Dec 28;528(1-3):27-36. doi: 10.1016/j.ejphar.2005.10.068.
66	Interleukin-2-induced antinociception in morphine-insensitive rats. Acta Pharmacol Sin. 2002 Nov;23(11):981-4.
67	Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes. BMC Immunol. 2006 Nov 21;7:27. doi: 10.1186/1471-2172-7-27.
68	Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol. 2002 Dec;133(1-2):124-31. doi: 10.1016/s0165-5728(02)00370-3.
69	opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes. J Neuroimmunol. 2013 Oct 15;263(1-2):35-42. doi: 10.1016/j.jneuroim.2013.07.012. Epub 2013 Jul 25.
70	1,25-Dihydroxyvitamin D3-regulated expression of genes involved in human T-lymphocyte proliferation and differentiation. Cancer Res. 1986 Nov;46(11):5827-31.
71	In vitro folate deficiency induces apoptosis by a p53, Fas (Apo-1, CD95) independent, bcl-2 related mechanism in phytohaemagglutinin-stimulated human peripheral blood lymphocytes. Br J Nutr. 2006 May;95(5):870-8. doi: 10.1079/bjn20051579.
72	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
73	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
74	Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
75	The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
76	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
77	Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
78	Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
79	Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
80	Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
81	Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
82	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
83	Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
84	Inorganic arsenic represses interleukin-17A expression in human activated Th17 lymphocytes. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):217-22. doi: 10.1016/j.taap.2012.05.004. Epub 2012 May 19.
85	Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009 Mar 16;206(3):535-48. doi: 10.1084/jem.20082293. Epub 2009 Mar 9.
86	Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.